In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 27-34

  Barbara, Cecilia ^a   Orlandi, Paola ^a   Bocci, Guido ^a   Fioravanti, Anna ^a   Di Paolo, Antonello ^a   Natale, Gianfranco ^a   Del Tacca, Mario ^a   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bile acid; Carboplatin; Cisplatin; Hepatoma; Mitoxantrone; Platinum complex

Indexed keywords

BILE ACID CONJUGATE; CARBOPLATIN; CISPLATIN; MITOXANTRONE; PLATINUM COMPLEX;

AGGRESSION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HEPATOMA CELL; IC 50; IN VITRO STUDY; IN VIVO CULTURE; LIVER CELL CARCINOMA; MALE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; BILE ACIDS AND SALTS; BODY WEIGHT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; ORGANOPLATINUM COMPOUNDS; PLATINUM; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TIME FACTORS;

EID: 33748956796     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.015     Document Type: Article

References (25)

1. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp. Neurol. 182 (2003) 12-20
2. Bianchi N., Ongaro F., Chiarabelli C., Gualandi L., Mischiati C., Bergamini P., and Gambari R. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem. Pharmacol. 60 (2000) 31-40
3. Criado J.J., Herrera M.C., Palomero M.F., Medarde M., Rodriguez E., and Marin J.J. Synthesis and characterization of a new bile acid and platinum(II) complex with cytostatic activity. J. Lipid Res. 38 (1997) 1022-1032
4. Criado J.J., Macias R.I., Medarde M., Monte M.J., Serrano M.A., and Marin J.J. Synthesis and characterization of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate. Bioconjug. Chem. 8 (1997) 453-458
5. Dominguez M.F., Macias R.I., Izco-Basurko I., de La Fuente A., Pascual M.J., Criado J.M., Monte M.J., Yajeya J., and Marin J.J. Low in vivo toxicity of a novel cisplatinursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther. 297 (2001) 1106-1112
6. Galanski M., Jakupec M.A., and Keppler B.K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem. 12 (2005) 2075-2094
7. Haller D.G. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Semin. Oncol. 31 (2004) 10-16
8. Ho Y.P., Au-Yeung S.C., and To K.K. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev. 23 (2003) 633-655
9. Ishikawa H., Kikkawa F., Tamakoshi K., Matsuzawa K., Kawai M., Suganuma N., and Tomoda Y. Distribution of platinum in human gynecologic tissues and lymph nodes after intravenous and intraarterial neoadjuvant chemotherapy. Anticancer Res. 16 (1996) 3849-3853
10. Kaneko T., Sakaguchi Y., Makino M., Matsuda H., Strebel F.R., Jenkins G.N., and Bull J.M. Optimal duration of whole body hyperthermia when combined with cisdiaminne- 1,1-cychlobutane dicarboxylate platinum (II) (carboplatin). Anticancer Res. 17 (1997) 1897-1901
11. Larena M.G., Martinez-Diez M.C., Monte M.J., Dominguez M.F., Pascual M.J., and Marin J.J. Liver organotropism and biotransformation of a novel platinumursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity. J. Drug Target 9 (2001) 185-200
12. Los G., Nagel J.D., and McVie J.G. Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study. Sel. Cancer Ther. 6 (1990) 73-82
13. Macias R.I., El-Mir M.Y., Monte M.J., Serrano M.A., Garcia M.J., and Marin J.J. Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). J. Control. Release 57 (1999) 161-169
14. Marin J.J., Herrera M.C., Palomero M.F., Macias R.I., Monte M.J., El-Mir M.Y., and Villanueva G.R. Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). J. Hepatol. 28 (1998) 417-425
15. Marin J.J., Palomero M.F., Herrera M.C., Macias R.I., Criado J.J., and Serrano M.A. In vitro cytostatic activity and DNA-interaction of the new liver organotropic complex chloro-bis-cholylglycinate-platinum (II). Anticancer Res. 18 (1998) 1641-1647
16. Momekov G., Bakalova A., and Karaivanova M. Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr. Med. Chem. 12 (2005) 2177-2191
17. Monte M.J., Dominguez S., Palomero M.F., Macias R.I., and Marin J.J. Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. J. Hepatol. 31 (1999) 521-528
18. Monte M.J., Ballestero M.R., Briz O., Perez M.J., and Marin J.J. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J. Pharmacol. Exp. Ther. 315 (2005) 24-35
19. Muggia F.M., and Fojo T. Platinums: extending their therapeutic spectrum. J. Chemother. 16 Suppl 4 (2004) 77-82
20. Paschke R., Kalbitz J., Paetz C., Luckner M., Mueller T., Schmoll H.-J., Mueller H., Sorkau E., and Sinn E. Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J. Inorg. Biochem. 94 (2003) 335-342
21. Ridet J.L., Pencalet P., Belcram M., Giraudeau B., Chastang C., Philippon J., Mallet J., Privat A., and Schwartz L. Effects of spinal cord X-irradiation on the recovery of paraplegic rats. Exp. Neurol. 161 (2000) 1-14
22. Sternberg C.N., Whelan P., Hetherington J., Paluchowska B., Slee P.H., Vekemans K., Van Erps P., Theodore C., Koriakine O., Oliver T., Lebwohl D., Debois M., Zurlo A., and Collette L. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9
23. Suto A., Kubota T., Fukushima M., Ikeda T., Takeshita T., Ohmiya H., and Kitajima M. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol. Rep. 15 (2006) 1517-1522
24. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4 (2005) 307-320
25. Zhang C.X., and Lippard S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 7 (2003) 481-489